Retracted: Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566.

Abstract

Retraction: "Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566" by R. M. J. Deacon, M. J. Hurley, C. M. Rebolledo, M. Snape, F. J. Altimiras, L. Farías, M. Pino, R. Biekofsky, L. Glass and P. Cogram. The above article, from Genes, Brain and Behavior, published online on 12th May 2017 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor in Chief, Andrew Holmes and John Wiley & Sons Ltd. The retraction has been agreed as all authors cannot agree on a revised author order, and at least one author continues to dispute the original order. In this case, the original article is being retracted on the grounds that the journal does not have permission to publish. Reference: Deacon, R. M. J., Hurley, M. J., Rebolledo, C. M., Snape, M., Altimiras, F. J., Farías, L., Pino, M., Biekofsky, R., Glass, L. and Cogram, P. (2017), Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566. Genes, Brain and Behavior. doi:10.1111/gbb.12373.

DOI: 10.1111/gbb.12373

Cite this paper

@article{Deacon2017RetractedNA, title={Retracted: Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566.}, author={Rob M J Deacon and Morgan J. Hurley and Carolina Mendoza Rebolledo and Michael Snape and Francisco J. Altimiras and Lisette Farias and M Pino and Rolf R. Biekofsky and Lelia Glass and P Cogram}, journal={Genes, brain, and behavior}, year={2017}, volume={16 7}, pages={739} }